August 5, 2015 – Aimmune Therapeutics announced today the pricing of its initial public offering at $16.00 per share. Trading is to begin tomorrow on NASDAQ under the symbol AIMT. Company press release. FLG partner: Victor Colunga.
East Hanover, N.J., June 30, 2022 — Novartis today announced that it has acquired Kedalion Therapeutics and its AcuStream™ technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. FLG client, Kedalion Therapeutics, is a clinical-stage,…Read More
“When I become CEO of TapInfluence in 2015, I knew there would be challenges trying to evolve the culture and changing the business model from a managed services business to a software as a service (SaaS) business. Most fail because of the amount of discipline required to stay the course despite potential disruptions in revenue, team dynamics, and customer relationships. As we evaluated the prospects of a new funding round, I needed a CFO who could be a leader and trusted business partner that was credible with my board of directors and potential investors, strategic to develop our business models, scenario planning and forecasts, and operationally focused to evolve to a SaaS business model. I was extremely pleased that my FLG Partner, Ken Chow and I closed our funding round with our board’s support at a strong valuation and on time. This made a huge difference for our business and could not have done without FLG’s support.”